Drugmaker Sarepta Therapeutics says it won't comply with a request from U.S. regulators to halt all shipments of its gene ...

U.S. regulators asked Sarepta Therapeutics on Friday to voluntarily halt shipments of its Elevidys gene therapy after a ...

U.S. regulators asked Sarepta Therapeutics on Friday to voluntarily halt shipments of its Elevidys gene therapy after a ...

Sarepta Therapeutics refuses the FDA request to halt its gene therapy shipments following a third patient death, challenging ...

A team of Chinese medical experts say they can produce anti-cancer cells directly inside the human body using gene therapy ...

Massachusetts-based Sarepta Therapeutics, facing scrutiny from regulators, is reducing its global workforce by 36% in an ...

Genascence’s GNSC-001 for knee osteoarthritis receives US FDA regenerative medicine advanced therapy designation: Palo Alto, California Saturday, July 19, 2025, 16:30 Hrs [IST] ...

The death of a 51-year-old man in the study follows two other deaths of Duchenne patients treated with Sarepta’s marketed ...

Rocket Pharma receives US FDA regenerative medicine advanced therapy designation for RP-A601 gene therapy: Cranbury, New Jersey Saturday, July 19, 2025, 15:00 Hrs [IST] Rocket Pha ...

The FDA asked Sarepta Therapeutics to halt shipments of its Elevidys gene therapy after a patient's death linked to a similar treatment. Sarepta will continue shipments for ambulatory patients but ...

(NASDAQ: OCGN) has announced that the first patient has been dosed in its Phase 2/3 GARDian3 clinical trial evaluating ...